Grammy-nominated singer-songwriter Aloe Blacc joined TechCrunch's Equity podcast to discuss his bold pivot from music stardom to founding a biotech venture.
His journey began after contracting COVID-19 despite being vaccinated and boosted, prompting him to seek better therapeutic solutions.
Aloe Blacc's Leap into Biotech Challenges
Blacc quickly learned that simply writing a check for biotech research is insufficient due to stringent regulatory demands for commercialization plans.
Philanthropy alone cannot advance science through clinical trials or secure licenses on university intellectual property, he explained.
Undeterred, Blacc is now bootstrapping a drug platform at Major Inc. specifically targeting pancreatic cancer, which claims 90% of its victims.
This merit-based field ignores his celebrity status, emphasizing rigorous science over fame—a point he welcomes as validation for true innovation.
With a background in healthcare consulting and partnerships like the University of Houston, Blacc draws on prior successes in antiviral research inspired by his COVID experience.
Future Outlook: AI, Fundraising, and Industry Impact
He is strategically delaying fundraising until peer-reviewed papers substantiate the platform's potential, planning to approach his network thereafter.
Blacc observes AI's transformative role in both biotech drug discovery and the music industry, accelerating development timelines dramatically.
This approach could democratize access to life-saving treatments, particularly for underserved pancreatic cancer patients facing dire prognoses.
His story highlights a growing trend of creators building startups rather than just investing, reshaping entrepreneurial landscapes across sectors.
Ultimately, Blacc's venture underscores biotech's unforgiving nature while inspiring cross-industry innovators to pursue high-impact missions.
Andrew Lee
